{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:06:42Z","timestamp":1784203602241,"version":"3.55.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world experience with low-level viremia (LLV) remains under reported, leading to limited knowledge about the clinical management and impact of persistent LLV on subsequent emergence of drug resistance and virologic failure (VF). The aim of this study was to assess the effect of bictegravir on the virologic outcomes in treatment-experienced people with HIV (PWHIV) with persistent LLV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>An observational, prospective study in which treatment-experienced PWHIV experiencing LLV were included after switch to BIC\/TAF\/FTC. Baseline demographic and clinical characteristics were collected from the participants\u2019 medical records. CD4 + T-cell counts, CD4\/CD8 ratios, and HIV-RNA levels were evaluated 2, 6, 12, 18, and 24 months after initiation of BIC\/TAF\/FTC. Statistical analysis of the data was performed using IBM Statistical Package for Social Sciences (SPSS), version 19.0 (IBM Corp., Armonk, NY, USA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total number of 31 PWHIV, 21 males, with a mean age of 47.08 \u00b1 7.48 years, were included. The current ART regimen before switch was based on Integrase Strand Transfer Inhibitors (INSTIs) in 30 PWH (96.8%). The mean CD4 + T-cell count after bictegravir initiation (619.45 \u00b1 181.71,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001) was significantly elevated compared to the baseline mean CD4 + T-cell count (485.85 \u00b1 166.92). Two months after bictegravir initiation, viral suppression was achieved at 58.1% (n = 18), and at 90.3% (n = 28) at 12 months, which was maintained at 18 and 24 months. A significant gradual elevation of CD4\/CD8 ratio was also observed (0.51 \u00b1 0.30 before switch vs 0.69 \u00b1 0.35 at 12 months,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of the present study indicate that BIC\/TAF\/FTC may improve the immunological response and reduce the proportion of PWHIV experiencing persistent LLV. Further studies in larger patient series are needed to determine the full beneficial role of bictegravir.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624251406062","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:12:27Z","timestamp":1765066347000},"page":"419-426","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bictegravir\u2019s effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-4811","authenticated-orcid":false,"given":"Vasilis","family":"Petrakis","sequence":"first","affiliation":[{"name":"Democritus University of Thrace, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Rafailidis","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Babaka","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorios","family":"Trypsianis","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panopoulou","family":"Maria","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Zisaki","sequence":"additional","affiliation":[{"name":"University General Hospital Alexandroupolis, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papazoglou","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-1090","authenticated-orcid":false,"given":"Periklis","family":"Panagopoulos","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace, Alexandroupolis, Evros, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.2004743"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570162X20666220216102943"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054551"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142923"},{"key":"e_1_3_6_6_2","first-page":"1","article-title":"Major revision version 13.0 of the European AIDS clinical society guidelines 2025","volume":"17","author":"Ambrosioni J","year":"2025","unstructured":"Ambrosioni J, Levi LI, Alagaratnam J, et al. Major revision version 13.0 of the European AIDS clinical society guidelines 2025. HIV Med 2025; 17: 1\u201315.","journal-title":"HIV Med"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30681-3"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2949"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm516"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/1087291041703692"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000230"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12814"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13446"},{"key":"e_1_3_6_14_2","volume-title":"ClinicalInfo.HIV.gov [Internet]","year":"2002","unstructured":"HHS panel on antiretroviral guidelines for adults and adolescents\u2014A working group of the office of aids research advisory council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIVS. [Updated 2025 sep 25]. In: ClinicalInfo.HIV.gov [Internet]: US Department of Health and Human Services; 2002. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586306\/"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae569"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab220"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae147"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002306"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003272"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-025-00743-2"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200404300-00005"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir353"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01217-12"},{"issue":"43","key":"e_1_3_6_25_2","first-page":"e13016","article-title":"Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-na\u00efve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: a retrospective cohort study","volume":"97","author":"Jacobson K","year":"2018","unstructured":"Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-na\u00efve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: a retrospective cohort study. M\u00e9d Sur 2018; 97(43): e13016.","journal-title":"M\u00e9d Sur"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu119"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13585"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251406062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624251406062","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251406062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:47:24Z","timestamp":1777675644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624251406062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/09564624251406062"],"URL":"https:\/\/doi.org\/10.1177\/09564624251406062","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]}}}